CERo Therapeutics stockholders approve share issuance and equity plan increase at special meeting

CERO THERAPEUTICS HOLDINGS, INC.

Ratified Wolf & Company as independent auditor for 2024, with 8.32M votes for.
Approved issuance of common stock upon conversion of Series A and B preferred and warrants.
Approved issuance under Committed Equity Financings arrangement.
Amended 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000.
All proposals passed with over 98% of votes cast in favor; quorum of 56.9% of shares.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shar at the 2024-04-30 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal 4. To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shares. FOR ABSTAIN AGAINST 8,234,447 5,614 134,041

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Seri at the 2024-04-30 meeting.

Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal 2. To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Series B convertible preferred stock, par value $0.0001 per share, (iii) the exercise of warrants to purchase Common Stock and (iv) the exercise of warrants to purchase 2,500 shares of Series A Preferred Stock and conversion of the underlying Series A Preferred Stock. FOR ABSTAIN AGAINST 8,308,766 6,621 58,715

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). at the 2024-04-30 meeting.

Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal 3. To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). FOR ABSTAIN AGAINST 8,303,706 6,581 63,815

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. at the 2024-04-30 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-04-30

Exact text from the filing

Proposal 1. To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. FOR ABSTAIN AGAINST 8,321,662 7,562 44,878

View on SEC.gov

555 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-038497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.